Zurueck zur Suche

Reporte zur Charge EW0167 SHC-VC

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

2Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
CA 2

VAERS 1328019

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge EW0167 SHC-VC

moderat
Staat
CA
Alter
20,0
Geschlecht
F
Eingang
28.08.2021
Impfdatum
13.05.2021
Beginn
14.05.2021
Tage bis Beginn
1,0
Dosis
2
Route/Site
- / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Ageusia Hypoaesthesia Paraesthesia oral SARS-CoV-2 test Swollen tongue Tongue pruritus

Symptomtext

Swelling of tongue; Some loss of taste; Tingling in tongue and numbness; Tingling in tongue and numbness; This is a spontaneous report from a contactable consumer (patient). A 20-years-old non-pregnant female patient received BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot Number: EW0167 SHC-VC and Expiration date was not reported), via an unspecified route of administration, administered in left arm on 13May2021 at 13:00 hours as dose 2, single (at the age of 20-years-old) for covid-19 immunisation. Patient had no medical history. Patient had no known allergies. Historical vaccine included BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot Number: EW0161 and Expiration date was not reported), via an unspecified route of administration, administered in left arm on 17Apr2021 at 14:00 hours as dose 1, single (at the age of 20-years-old) for covid-19 immunisation. Concomitant medication(s) in two weeks included escitalopram and duloxetine hydrochloride (Cymbalta) (both taken for an unspecified indication, start and stop date were not reported). Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, patient was not diagnosed with COVID-19. On 14May2021, patient had swelling of tongue, some loss of taste, tingling in tongue and numbness. On 17May2021, patient had been tested for COVID-19 by nasal swab and result was negative. Patient received no treatment for all the events. All events were assessed as non-serious by the reporter. The outcome of all the events was recovering. Follow-up attempts are completed. No further information is expected.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Paraesthesia oral
Hospital-Tage
-
Labordaten
Test Date: 20210517; Test Name: Nasal Swab; Test Result: Negative
Aktuelle Erkrankungen
-
Vorgeschichte
Comments: List of non-encoded Patient Relevant History: Patient Other Relevant History 1: None, Comment: None
Andere Medikamente
ESCITALOPRAM; CYMBALTA
Allergien
-
Vorherige Impfungen
-

VAERS 1652223

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge EW0167 SHC-VC

mild
Staat
CA
Alter
16,0
Geschlecht
F
Eingang
28.08.2021
Impfdatum
13.05.2021
Beginn
15.05.2021
Tage bis Beginn
2,0
Dosis
2
Route/Site
- / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Dry skin Pruritus Skin exfoliation Urticaria

Symptomtext

drying; peeling skin on face; Itchiness/severe itchiness; hives in arms; This is a spontaneous report from a contactable consumer, the patient. A 16-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0167 SHC-VC) via an unspecified route of administration in the right arm on 13May2021 at 00:00 (at the age of 16-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included diphenhydramine, paracetamol, phenylpropanolamine hydrochloride (BENADRYL) and hydrocortisone cream (MANUFACTURER UNKNOWN); both from an unknown date for an unspecified indication. The patient had no known allergies. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0159) via an unspecified route of administration in the right arm on 22Apr2021 at 00:00 (at the age of 16-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15May2021 at 13:00, 2 days after vaccination, the patient experienced itchiness, hives in arms. On 15May2021, on day 4, the patient experienced severe itchiness, drying and peeling skin on face. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events and included treatment with OTC hydrocortisone cream and Benadryl. The clinical outcome of the events itchiness, hives in arms, severe itchiness, drying, and peeling skin were recovering. No follow-up attempts are needed. No further information is expected.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pruritus
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
BENADRYL; HYDROCORTISONE
Allergien
-
Vorherige Impfungen
-